The impact of the pharmacological activation of mouse PPARα in the context of obesity-induced hepatic inflammation is also reviewed as well as the potential relevance of PPARβ/δ as a molecular drug target to fight liver inflammation in the case of nonalcoholic fatty liver disease. Here, PPARA is linked to obesity due to melanocortin 4 receptor deficiency.